Nations Financial Group Inc. IA ADV Acquires 2,025 Shares of Cencora, Inc. $COR

Nations Financial Group Inc. IA ADV grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 14.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 16,027 shares of the company’s stock after acquiring an additional 2,025 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Cencora were worth $5,009,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in COR. Atlantic Edge Private Wealth Management LLC lifted its stake in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its stake in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the last quarter. Caldwell Trust Co purchased a new position in shares of Cencora in the second quarter worth about $46,000. Salomon & Ludwin LLC lifted its stake in shares of Cencora by 638.1% in the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after acquiring an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC boosted its holdings in Cencora by 3,975.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after acquiring an additional 159 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Robert W. Baird set a $415.00 target price on shares of Cencora in a report on Tuesday. Barclays initiated coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. TD Cowen increased their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, JPMorgan Chase & Co. raised their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $381.42.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,317 shares of company stock worth $7,009,260 over the last 90 days. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

COR opened at $354.96 on Friday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a market capitalization of $68.86 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The stock’s 50 day moving average price is $349.64 and its 200-day moving average price is $319.94. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.